Amifostine in Treating Women With Ovarian, Peritoneal, Cervical, Fallopian Tube, Uterine, or Endometrial Cancer

Stopped early · Phase 2

Conditions studied: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Neurotoxicity, Ovarian Cancer, Primary Peritoneal Cavity Cancer, Sarcoma

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of amifostine in reducing the risk of side effects caused by cisplatin and paclitaxel in treating women who have ovarian, peritoneal, cervical, fallopian tube, uterine, or endometrial cancer.

Key facts

Study ID

NCT00003624

Run by

Gynecologic Oncology Group

Starts

1998-12-01

Last updated by the study team

2013-04-11

Who can join

Age: any. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Chao Family Comprehensive Cancer Center — Orange, California, United States
• Vincent T. Lombardi Cancer Research Center, Georgetown University — Washington D.C., District of Columbia, United States
• Emory University Hospital - Atlanta — Atlanta, Georgia, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Indiana University Cancer Center — Indianapolis, Indiana, United States
• Washington University School of Medicine — St Louis, Missouri, United States
• Lineberger Comprehensive Cancer Center, UNC — Chapel Hill, North Carolina, United States
• Cleveland Clinic Cancer Center — Cleveland, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.